DrugPatentWatch Database Preview

Drugs in Development Information for GWP42003-P

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug GWP42003-P?

GWP42003-P is an investigational drug.

There have been 25 clinical trials for GWP42003-P. The most recent clinical trial was a Phase 3 trial, which was initiated on December 9^th 2019.

The most common disease conditions in clinical trials are Syndrome, Epilepsy, and Seizures. The leading clinical trial sponsors are GW Research Ltd, Augusta University, and State of Georgia.

There are eight hundred and two US patents protecting this investigational drug and four international patents.

Summary for GWP42003-P

US Patents	802
International Patents	4,265
US Patent Applications	2,052
WIPO Patent Applications	1,314
Japanese Patent Applications	5
Clinical Trial Progress	Phase 3 (2019-12-09)
Vendors	24

Recent Clinical Trials for GWP42003-P

Title	Sponsor	Phase
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment	GW Research Ltd	Phase 2
An Open-label Extension Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome	GW Research Ltd	Phase 3
Investigation of Cognitive Outcomes With Cannabidiol Oral Solution	GW Research Ltd	Phase 4

See all GWP42003-P clinical trials

Clinical Trial Summary for GWP42003-P

Top disease conditions for GWP42003-P

Top clinical trial sponsors for GWP42003-P

See all GWP42003-P clinical trials

US Patents for GWP42003-P

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
GWP42003-P		Pharmaceutical formulations	GW Pharma Limited (Cambridge, GB)
GWP42003-P		Compositions and methods for treating chronic inflammation and inflammatory diseases	Infirst Healthcare Limited (London, GB)
GWP42003-P		Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols	KANNALIFE SCIENCES, INC. (Huntington, NY)
GWP42003-P		METAP2 inhibitors and methods of treating obesity	SynDevRx, Inc. (Cambridge, MA)
GWP42003-P		Compositions, uses and methods for making them

International Patents for GWP42003-P

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
GWP42003-P	Australia	2002231970	2021-02-14
GWP42003-P	Canada	2438097	2021-02-14
GWP42003-P	Canada	2533400	2021-02-14
GWP42003-P	China	1886117	2021-02-14
GWP42003-P	Cyprus	1115072	2021-02-14